News

Passage Bio received the feedback on a proposal to amend the upliFT-D protocol in the context of a Type C meeting process with the FDA.

Review top news and interview highlights from the week ending July 19, 2024.

In observance of Sarcoma Awareness Month, held annually in July, we took a look back at the past year's news in cell/gene therapy for this cancer.

The associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.

The gene therapy has continued to demonstrate efficacy in updated data from the phase 2 PRISM trial.

The chief scientific officer of Caribou Biosciences discussed results from preclinical research evaluating the gene editing approach.

Longeveron will present updated data from the phase 2a CLEAR MIND study at AAIC 2024 at the end of July.

The chief medical officer at Creyon Bio overviewed the development of an allele-selective TNPO2 protein for a single patient with a de novo pathology.

BRG01 is engineered to target the EBV antigen, which is frequently expressed on nasopharyngeal carcinoma tumor cells.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment

Patient enrollment is anticipated to begin in the first quarter of 2025.

The senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.

Data from the high-dose cohort of a phase 1/2 clinical trial in South Korea will be shared in Fall 2024.

Despite the improvements, Lexeo was unable to discern a benefit on cardiovascular fitness and Peak VO2 from LX2006 with current measurements.

The medical director of clinical development at AskBio discussed setbacks in the phase 1 trial of AB-1002 gene therapy.

RG6501/OpRegen was well-tolerated, with no serious treatment-related AEs reported in follow-up data from a phase 1/2 trial.

The chief scientific officer of Caribou Biosciences discussed the company’s platform for genome editing.

Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute, pointed out that genetic forms of PD are relatively well-understood compared to other types.

In light of the CTN clearance, Interius expects to initiate plans for a phase 1 clinical trial (INVISE) for INT2104 within the final quarter of 2024.

1x1015 vg 4D-710 has been identified as the maximum tolerated dose in the AEROW trial.

Review top news and interview highlights from the week ending July 12, 2024.

GT Biopharma anticipates initiating the phase 1 clinical trial in the second half of 2024.

The chairman and chief executive officer of NKGen discussed the new clinical study design for evaluating the NK cell therapy in PD.

Tr1X reported that the first patient has cleared the trial’s safety period successfully, having experienced no serious adverse events.

The PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen discussed her work presented at the ASGCT 2024 meeting.

The open-label, single-arm, multisite NEXICART-2 study will aim to enroll around 40 participants in total.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.